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BDnF genotype interacts with Motor 
Function to influence rehabilitation 
responsiveness Poststroke
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Peter R. Schofield1,2 and Penelope A. McNulty1,2*
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Background: Persistent motor impairment is common but highly heterogeneous 
poststroke. Genetic polymorphisms, including those identified on the brain-derived 
neurotrophic factor (BDNF) and apolipoprotein E (APOE) genes, may contribute to this 
variability by limiting the capacity for use-dependent neuroplasticity, and hence rehabili-
tation responsiveness.
Objective: To determine whether BDNF and APOE genotypes influence motor improve-
ment facilitated by poststroke upper-limb rehabilitation.
Methods: BDNF-Val66Met and APOE isoform genotypes were determined using leu-
kocyte DNA for 55 community-dwelling patients 2–123 months poststroke. All patients 
completed a dose-matched upper-limb rehabilitation program of either Wii-based 
Movement Therapy or Constraint-induced Movement Therapy. Upper-limb motor func-
tion was assessed pre- and post-therapy using a suite of functional measures.
results: Motor function improved for all patients post-therapy, with no difference 
between therapy groups. In the pooled data, there was no significant effect of BDNF or 
APOE genotype on motor function at baseline, or following the intervention. However, a 
significant interaction between the level of residual motor function and BDNF genotype 
was identified (p = 0.029), whereby post-therapy improvement was significantly less for 
Met allele carriers with moderate and high, but not low motor function. There was no 
significant association between APOE genotype and therapy outcomes.
conclusion: This study identified a novel interaction between the BDNF-Val66Met 
polymorphism, motor-function status, and the magnitude of improvement with reha-
bilitation in chronic stroke. This polymorphism does not preclude, but may reduce, the 
magnitude of motor improvement with therapy, particularly for patients with higher, but 
not lower residual motor function. BDNF genotype should be considered in the design 
and interpretation of clinical trials.
Keywords: motor rehabilitation, upper limb, stroke genetics, apolipoprotein e, brain-derived neurotrophic factor
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inTrODUcTiOn
Motor impairment is a common, disabling, and inherently het-
erogeneous outcome of stroke (1, 2). Patients typically present 
across a broad clinical continuum and undergo variable and often 
incomplete recovery of motor function over time and in response 
to targeted rehabilitation (3). Predicting poststroke prognosis and 
recovery potential has gained a prominent research focus, with 
the most common predictive factors being measures of lesion size 
(4, 5), location (6, 7), corticospinal tract integrity (8, 9), and initial 
impairment severity (10, 11). While more extensive corticospinal 
tract damage and more severe baseline impairment are generally 
associated with poorer prognosis poststroke (10–12), these factors 
alone cannot fully explain the degree of variability in poststroke 
motor outcomes and patients’ response to motor therapies (3, 13). 
In order to optimize rehabilitation and thus maximize poststroke 
recovery, a deeper understanding of the factors that mediate this 
residual variability is necessary.
Genetic variation may account for some of the unexplained 
variance in stroke recovery. In particular, single-nucleotide 
polymorphisms (SNPs) in genes related to cortical plasticity and 
neural repair could influence an individual’s capacity for use-
dependent plasticity, and hence their responsiveness to poststroke 
rehabilitation [for review, see Ref. (14)]. Numerous genes of 
interest continue to emerge in the growing field of stroke genetics 
(14, 15). Here, we have adopted a candidate gene approach based 
on two genetic factors with the strongest evidence in subacute 
stroke and extended this investigation into the chronic setting. 
The candidate genes are the brain-derived neurotrophic factor 
(BDNF) and apolipoprotein E (APOE) genes (16).
The BDNF gene encodes for the neurotrophin most abundantly 
expressed in the brain and involved in neuronal differentiation, 
survival, and synaptic plasticity (17–19). Approximately 30% of 
the Caucasian population and a higher percentage of the Asian 
population possess an SNP (rs6265) in the BDNF gene, resulting 
in a valine to methionine substitution at codon 66, the Val66Met 
polymorphism (20). This polymorphism alters the intracellular 
trafficking and activity-dependent release of BDNF (21, 22), and 
in healthy cohorts has been associated with a reduced capacity 
for use-dependent plasticity in the motor cortex (23–26) and 
impaired motor learning (26).
The BDNF-66Met allele may be detrimental to recovery follow-
ing stroke (14), but the evidence to date remains contentious (27). 
Studies have primarily focused on subacute outcomes following 
spontaneous recovery, where both a significant negative associa-
tion between Val66Met and stroke outcome (28–31) and a modest 
or negligible effect have been reported (16, 32–34). There is scant 
evidence of whether the Val66Met polymorphism influences 
long-term stroke recovery or responsiveness to targeted therapies. 
There is some suggestion that it may alter patient responsiveness to 
non-invasive brain stimulation (35, 36), but to date, no significant 
effect of this genotype on motor therapy has been identified (13).
Single-nucleotide polymorphisms within the APOE gene 
are less prevalent but potentially stronger genetic mediators of 
poststroke recovery (16). This gene encodes for a glycoprotein 
primarily involved in lipid transport and metabolism, but it 
also plays an important role in neuronal repair and synaptic 
remodeling (37, 38). Two SNPs (rs429358 and rs7412) in the 
APOE gene give rise to three distinct APOE isoforms, ε2 (Cys112/
Arg158Cys), ε3 (Cys112/Arg158), and ε4 (Cys112Arg/Arg158) (39). The 
ε4 isoform is present in only 10–20% of the population (40) but 
has been strongly implicated in the risk for Alzheimer’s disease 
(41, 42) and cardiovascular pathology (40, 43). Studies of APOE 
ε4 in stroke have mainly focused on stroke incidence rather than 
outcome (43), although emerging evidence suggests that the ε4 
allele may have a detrimental effect on poststroke recovery (16, 
44–46). Like BDNF, it remains uncertain whether APOE geno-
type can influence motor function and rehabilitation outcomes 
more chronically poststroke (13).
Here, we investigated whether BDNF and APOE genotype 
influence how stroke patients with stable motor function respond 
to a targeted protocol of upper-limb motor therapy poststroke. 
Data were collected from a pooled cohort of patients who received 
a dose-matched protocol of either Constraint-induced Movement 
Therapy, the current gold standard in upper-limb stroke rehabili-
tation, or Wii-based Movement Therapy, recently shown to be an 
engaging and equally efficacious therapy alternative (47). Given 
that no differences were demonstrated in any measure of upper-
limb motor function between these two therapies (47), we did 
not expect to see differences according to therapy type, but rather 
according to genotype. We hypothesized that all patients would 
make some degree of motor improvement post-therapy, although 
those who possessed the BDNF-66Met or APOE-ε4 alleles would 
have less improvement with a standardized dose of therapy.
MaTerials anD MeThODs
Participants
Genetic samples were obtained from 55 community-dwelling 
stroke patients aged 18–83 years (61.4 ± 13.8 years, mean ± SD) 
and 2–123 months poststroke (21.0 ± 3.1 months, mean ± SEM). 
All had suffered an unilateral stroke resulting in hemiparesis 
involving an upper limb. The present study was conducted as 
an optional adjunct to ongoing therapy trials in our laboratory. 
Inclusion criteria included (i) ≥14 years of age, (ii) medically stable, 
and (iii) cognitively competent as assessed by a Mini-Mental State 
Examination score ≥24. Exclusion criteria included (i) enrollment 
in any other formal rehabilitation program during the trial, (ii) 
comorbidities significantly affecting upper-limb sensorimotor 
function (e.g., diabetic neuropathy), and (iii) known infection 
with the blood-borne viruses HIV and/or hepatitis. All participants 
gave informed, written consent, and the study was approved by the 
Human Research Ethics Committee of St Vincent’s Hospital Sydney 
and conducted in accordance with the Declaration of Helsinki.
genotyping
A single venous blood sample (9 mL) was collected from each 
patient either pre- or post-therapy. Genomic DNA was isolated 
from leukocytes using the Autopure LS nucleic acid purification 
system (QIAgen, Hilden, Germany) at Genetic Repositories 
Australia, Sydney. DNA isolates were then amplified and used in 
separate assays to genotype each sample for the BDNF-Val66Met 
polymorphism and APOE-ε4 allele, as described below.
TaBle 1 | aPOe genotype, based on allelic distribution at two snP loci.
rs429358 rs7412 aPOe 
genotype
n (%)
nucleotides amino 
acid 112
nucleotides amino acid 
158
T/T Cys/Cys T/T Cys/Cys ε2/ε2 1 (1.8)
T/T Cys/Cys C/T Arg/Cys ε2/ε3 8 (14.8)
T/T Cys/Cys C/C Arg/Arg ε3/ε3 36 (66.7)
T/C Cys/Arg C/T Arg/Cys ε2/ε4 2 (3.7)
T/C Cys/Arg C/C Arg/Arg ε3/ε4 7 (12.9)
C/C Arg/Arg C/C Arg/Arg ε4/ε4 0 (0)
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BDNF Genotyping
Isolated DNA was amplified using polymerase chain reac-
tions (PCR) with the forward and reverse primers 5′-TGTAT 
TCCTCCAGCAGAAAGAGAA-3′ and 5′-AAAGAAGCAA 
ACATCCGAGGAC-3′, respectively. Reactions were performed 
using 40 ng of genomic DNA in a 25-μL total volume containing 
50 mM MgCl2, 2.5 mM deoxynucleotide triphosphates, 10 pmol 
of each of the primers, and Platinum Taq polymerase (Life 
Technologies, Australia). The amplified 277  bp DNA fragment 
was digested using the restriction enzyme AflIII to give a 71-bp 
digestion control band in addition to a 206-bp band for the Met 
allele or 129 and 77 bp bands for the Val allele. PCR products 
were separated on 4% agarose gels stained with RedSafe (Intron 
Biotechnology, South Korea) and viewed using a UV transillumi-
nator and Image Lab software (Bio-Rad Laboratories, Australia). 
Genotypes were read by two blinded assessors and the results 
corroborated to ensure reliability. In addition, a blind repeat of 
the BDNF assay was conducted on all samples. No discrepancies 
were identified for any sample between the two blinded assessors 
or between the repeat assays.
APOE Genotyping
TaqMan SNP genotyping assays, C_3084793_20 and C_904973_10 
(AB Applied Biosystems, Life Technologies, Australia), were 
conducted on genomic DNA to genotype the two APOE-SNPs 
rs429358 and rs7412, respectively. The composition of these two 
SNPs was used to determine APOE genotype, as outlined in 
Table 1. Allelic discrimination assays were performed in 5 μL total 
volume in 384-well plates, using SNP specific primers and probes 
on an ABI 7900HT Fast Real-Time PCR instrument according 
to manufacturer’s instructions (AB Applied Biosystems, Life 
Technologies, Australia). Blind repeats of both assays were com-
pleted to ensure reliability of the results. As for BDNF, all APOE 
genotypes were read by two independent assessors with 100% 
inter-rater and inter-assay concordance.
Motor-Function assessments
A suite of functional assessments was used to quantify motor abil-
ity of the more-affected upper limb. This included the timed tasks 
of the Wolf Motor Function Test (WMFT-tt) (48), upper-limb 
motor Fugl-Meyer Assessment (FMA) (49), and Motor Activity 
Log Quality of Movement scale (MALQOM) (50). These assess-
ments were completed by all patients both immediately before 
(pre-therapy/baseline) and after (post-therapy) a 14-day protocol 
of upper-limb rehabilitation (details below).
During pre-therapy assessments, two tests of dexterity were 
used to classify the level of upper-limb motor function, according to 
the objective classification scheme developed by Thompson-Butel 
and colleagues (51). In brief, patients unable to pick up and move 
>1 block on the box and block test (BBT) were classified with low 
motor function, while those who could move >1 block progressed 
to the more challenging grooved pegboard test. Patients unable 
to complete the grooved pegboard were classified with moderate 
motor function while those who successfully placed all 25 pegs 
were classified with high motor function (see Figure 1A).
Upper-limb Therapy
All patients completed a dose-matched 14-day protocol of 
either Wii-based Movement Therapy (n  =  40) or modified 
Constraint-induced Movement Therapy (n  =  15), as part of 
ongoing rehabilitation trials within the authors’ laboratory 
group. Therapy allocation was determined by the rehabilitation 
trial each patient was enrolled in and was not influenced by this 
adjunct genetic study. Of the present cohort, 28 patients were 
randomly allocated to either Wii-based Movement Therapy 
or modified Constraint-induced Movement Therapy (13 and 
15 patients, respectively), as part of a randomized-controlled 
trial comparing these two-therapy protocols (47). The remain-
ing 27 patients were enrolled in trials specifically investigating 
Wii-based Movement Therapy. Therapy outcomes for patients in 
the present study appear in the following publications: McNulty 
and colleagues (47) (n = 29), Shiner and colleagues (52) (n = 4), 
Thompson-Butel and colleagues (53) (n = 3), and n = 19 remain 
unpublished.
Between-therapy differences were not anticipated in the 
present study because the two therapies are founded on the same 
core principles, were identically dose matched, and random 
patient allocation was performed (47). For both therapies, 10 
formal therapy sessions of 60-min duration were administered 
by an Accredited Exercise Physiologist on consecutive weekdays, 
specifically targeting movement of the more-affected hand and 
arm. Formal therapy was augmented by progressively increasing 
home practice which began on day 2 of the protocol and contin-
ued until day 14 (see Figure 1B).
Wii-based Movement Therapy uses the Nintendo Wii and Wii 
Sports program (Nintendo, Japan) under therapist guidance as a 
structured upper-limb rehabilitation tool (47, 54, 55). Patients 
operate the controller using only the more-affected hand and 
interact with the games of Wii-golf, -bowling, -baseball, -boxing, 
and  -tennis using targeted movements of the more-affected arm. 
Modified Constraint-induced Movement Therapy promotes forced 
use of the more-affected hand and arm by constraining the less-
affected hand in a padded mitt for up to 90% of waking hours. 
Constraint therapy and home-practice activities involve part-task 
training based on object manipulation with a focus on movement 
speed (56, 57).
Data analysis
Assay data were used to classify each patient as either a carrier or 
non-carrier of the BDNF-66Met and APOE-ε4 alleles, pooling 
FigUre 1 | study protocol. (a) Schematic representation of the objective classification scheme developed by Thompson-Butel and colleagues (51). The box and 
block test (BBT) and grooved pegboard were used prior to therapy to classify each patient with low, moderate, or high motor function. (B) All patients completed a 
dose-matched 14-day protocol of upper-limb rehabilitation, involving 10 formal therapy sessions and progressively increasing home practice (white squares 
represent weekends). Functional motor ability was assessed pre- and post-therapy, via the Wolf Motor Function Test timed tasks, the upper-limb motor Fugl-Meyer 
Assessment, and the Motor Activity Log Quality of Movement Scale. A single blood sample was collected from each patient for BDNF and APOE genotyping.
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homozygotes and heterozygotes for each polymorphism (16). 
Since there were no differences in either baseline motor func-
tion or therapy improvements between patients who completed 
Wii-based Movement Therapy and modified Constraint-induced 
Movement Therapy, all analyses were conducted on the combined 
patient cohort. Functional assessment data were not normally 
distributed and could not be transformed to a normal distribu-
tion; therefore, non-parametric statistical methods were used 
for analyses. At baseline, Mann–Whitney U tests were used to 
assess differences in age and pre-therapy motor function between 
carriers and non-carriers of each allele, while Chi-squared 
analyses were used to assess between-group differences in cat-
egorical variables including sex, ethnicity, and stroke etiology. 
Wilcoxon Signed-Rank tests were used to examine changes in 
functional movement ability induced by therapy. Generalized 
linear mixed models were then used to investigate the influence 
of genotype and motor function on improvements with therapy 
assessed using the WMFT-tt and FMA. Separate models were 
implemented for each gene (BDNF, APOE), where the depend-
ent variable was post-therapy score, controlling for pre-therapy 
score and with fixed factors of genotype (carrier, non-carrier), 
and motor functional classification (low, moderate, and high). 
A fixed interaction between genotype and motor functional 
classification was also entered into the model for BDNF, but the 
sample size precluded a similar analysis for APOE (see Results). 
All statistical analyses were conducted on raw data using SPSS 21 
software (IBM, USA), and differences were considered significant 
when p <  0.05. Parametric data are reported as mean ±  SEM, 
while non-parametric data are reported as median (interquartile 
range) in the text, and presented as mean ± SEM in figures for 
greater clarity.
resUlTs
genotype
Brain-derived neurotrophic factor and APOE genotypes could be 
determined for 54/55 patients, due to insufficient DNA yield and 
quality for one patient sample. Twenty-seven patients were iden-
tified as Val/Val homozygotes, 24 as Val/Met heterozygotes, and 3 
as Met/Met homozygotes. Thus, 27 patients possessed at least one 
copy of the BDNF-66Met allele (“Met carriers”), while 27 did not 
(“non-carriers”). For APOE, 9 patients were identified as ε4 car-
riers, and 45 as non-ε4 carriers (see Table 2 for full breakdown). 
Despite being sampled from a multi-ethnic population, both 
BDNF and APOE genotype frequencies were in Hardy–Weinberg 
equilibrium (BDNF: χ2 =  0.25, p =  0.617, APOE: χ2 =  0.562, 
p = 0.453) and conformed to expected population rates (20, 40).
Baseline Motor Function
Demographic characteristics and baseline motor function for 
carrier/non-carrier groups are reported in Table  2. A single 
subject was <3 months poststroke, and stability of pre-therapy 
TaBle 2 | Demographic characteristics and baseline motor function, according to BDnF-Val66Met and aPOe-ε4 status.
BDnF Val66Met APOE ε4 all
Met carriers non-Met-carriers p Value ε4 carriers non ε4 carriers p Value
n (%) 27 (50) 27 (50) – 9 (16.7) 45 (81.8) – 54 (100)
Age 59.1 ± 16.8 63.6 ± 10.0 0.28 62.4 ± 9.6 61.2 ± 14.6 0.84 61.4 ± 13.8
Sex (F:M) 6:21 7:20 0.82 2:7 11:34 0.77 13:41
Ethnicity (Caucasian:Asian:Hispanic) 20:7:0 25:1:1 0.20 8:1:0 37:7:1 0.73 45:8:1
Dominant side (right:left) 24:3 26:1 0.30 8:1 42:3 0.64 50:4
More-affected side (right:left) 14:13 13:14 0.16 6:3 21:24 0.08 27:27
Stroke type (isch:haem) 18:9 20:7 0.55 7:2 31:14 0.59 38:16
Months poststroke 29.4 ± 4.5 28.8 ± 5.5 0.82 22.4 ± 4.8 30.5 ± 4.1 0.77 21.0 ± 3.1
Motor function, n
Low 9 10 0.81 1 18 0.09 19 (35.2)
Moderate 8 9 5 12 17 (31.5)
High 10 8 3 15 18 (33.3)
Pre-therapy WMFT-tt (s) 38.7 ± 7.3 42.3 ± 7.9 0.46 24.6 ± 10.0 43.4 ± 6.0 0.14 40.0 ± 5.3
Pre-therapy FMA 46.1 ± 3.6 42.0 ± 3.9 0.36 50.0 ± 5.4 42.8 ± 2.9 0.35 44.1 ± 2.6
Age is reported as mean ± SD, remaining data are reported as mean ± SEM.
Isch, ischemic; haem, haemorrhagic; WMFT-tt, mean time for the Wolf Motor Function Test timed tasks (maximum time of 120 s where lower time indicates better motor function); 
FMA, upper-limb Fugl-Meyer Assessment (maximum score 66).
Motor function classified according to the scheme of Thompson-Butel and colleagues (51).
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motor function was confirmed by repeat pre-baseline and 
 baseline motor function assessments 14  days apart. The 
remainder of the cohort were all >3 months poststroke, with an 
average of 21.0 ± 3.1 months poststroke. The pooled cohort was 
heterogeneous for upper-limb motor function, whereby baseline 
WMFT-tt mean scores ranged from 1.9 to 113.1  s (maximum 
time is 120 s). This heterogeneity was well balanced across BDNF/
APOE carriers and non-carriers, with no significant differences 
between groups for any demographic variable or any measure 
of motor function at baseline, for either BDNF or APOE (see 
Table  2). Similarly, as in previous work (47), there were no 
significant differences in motor function at baseline according to 
therapy allocation (Wii-based Movement Therapy vs. modified 
Constraint-induced Movement Therapy: WMFT-tt, p  =  0.83; 
FMA, p = 0.76; MALQOM, p = 0.73).
Motor improvements with Therapy
Motor function significantly improved across the cohort 
post-therapy on all measures tested. Median time for the 
WMFT-tt reduced from 22.3  s (4.0–81.6) to 20.4  s (2.8–74.4) 
(p  <  0.001), indicating faster and more efficient movement 
post-therapy. Similarly, upper-limb FMA scores increased 
from 48.0 (26.3–62.0) to 54.0 (30.3–62.8) pre- to post-therapy 
(p <  0.001). These improvements were evident in all patients 
and translated to improved performance of activities of daily 
living using the more-affected upper limb, as quantified using 
the MALQOM (57.7 ±  6.4–84.1 ±  5.8 pre- to post-therapy, 
p < 0.001) (see Figure 2). There were no differences between 
Wii-based Movement Therapy and modified Constraint-
induced Movement Therapy patients for any measure of 
therapy-induced improvement (WMFT-tt, p  =  0.61; FMA, 
p = 0.47; MALQOM, p = 0.41).
influence of genotype and Motor Function 
on improvements with Therapy
Brain-Derived Neurotrophic Factor
For the WMFT-tt data, generalized linear mixed modeling 
identified a significant fixed effect of baseline motor function 
on therapy-induced improvement [F(2,47) = 3.32, p = 0.045], 
whereby patients with high and moderate motor function made 
greater improvements than those with low motor function on this 
assessment. No significant main effect of BDNF genotype was 
identified for the cohort as a whole [F(1,47) = 0.439, p = 0.15]. 
However, a significant interaction between BDNF genotype 
and motor function was identified [F(2,47) = 3.81, p = 0.029], 
whereby the BDNF-Met allele had an effect on therapy-induced 
improvements for patients with high (p = 0.046) and moderate 
(p = 0.008), but not low motor function (see Figure 3A). Met 
carriers with high and moderate motor function made propor-
tionally less improvement than respective non-carriers (high: 
13.8 ± 6.8 vs. 25.2 ± 8.9%; moderate: 8.9 ± 4.7 vs. 37.3 ± 7.5%), 
while Met carriers/non-carriers with low motor function 
made comparable post-therapy gains (7.0 ± 3.7 vs. 3.8 ± 2.4%, 
respectively).
To ensure that this genotype by motor-function interaction 
was not driven by an artifact of test sensitivity, generalized linear 
mixed modeling was also performed using FMA data, which is a 
more salient measure of motor improvement for patients with low 
motor function than the WMFT-tt (58). The interaction between 
BDNF genotype and motor function did not reach statistical 
significance in the FMA model [F(2,47) = 2.071, p = 0.137] but 
the same pattern was observed, whereby the presence of the Met 
allele appeared to associate with less proportional improvement 
post-therapy for patients with high and moderate, but not low 
motor function (Figure 3B).
FigUre 2 | Pre- and post-therapy motor function. (a,B) contain mean data and SEs, (c) contains individual patient data (lines) with mean (squares) and SEs. 
(a) WMFT-tt mean times pre- (gray) and post-therapy (white), where lower time indicates better motor function. (B) FMA scores pre- and post-therapy, where higher 
score indicates better motor function, and dotted line indicates the maximum test score of 66. (c) Pre- and post-therapy MALQOM scores for all patients illustrating 
the wide range of motor function within the cohort, spanning the entire test range of 0–150. Significant improvement pre- to post-therapy was evident on all three 
measures (***p < 0.001).
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Apolipoprotein E
Given the demographic breakdown of ε4 carriers (n = 9 in total, 
with only one patient with low motor function, see Table 2), our 
sample size was not sufficient to examine the interaction between 
APOE genotype and motor function in the mixed model. Instead, 
only the main fixed effects of motor function and APOE genotype 
for pooled ε4 carriers vs. non-carriers were investigated. There 
was a trend for a fixed effect of motor-functional classification on 
post-therapy improvements when quantified using the WMFT-tt 
[F(2,50) =  3.03, p =  0.057]. However, no significant effect of 
APOE genotype on post-therapy improvement was evident when 
quantified using either the MALQOM [F(1,50) = 0.26, p = 0.61] 
or the FMA [F(1,50) = 0.45, p = 0.51].
DiscUssiOn
This study explored the relationships between BDNF and APOE 
genotype, chronic motor status, and motor improvement following 
a 14-day protocol of upper-limb stroke therapy. In a heterogeneous, 
community-dwelling stroke cohort, we saw no effect of either the 
BDNF-66Met or the APOE-ε4 allele on patients’ level of residual 
voluntary motor function at baseline. Similarly, BDNF and APOE 
genotype did not significantly influence the magnitude of post-
therapy improvements for the pooled cohort data. However, when 
patients were classified according to their baseline level of residual 
voluntary motor function, we identified a novel interaction between 
BDNF genotype and therapy improvements, whereby BDNF-Met 
carriers achieved less improvement relative to non-carriers among 
those patients with high and moderate, but not low motor function 
(Figure 3). This is the first demonstration that the BDNF-Val66Met 
polymorphism may have a differential effect on rehabilitation respon-
siveness depending on baseline motor function. These data suggest 
that different mechanisms of recovery mediate improvements for 
patients with different levels of residual motor function and illustrate 
that motor-function status should be considered together with BDNF 
genotype during the design and stratification of clinical trials.
an interaction between BDnF genotype 
and Poststroke Motor Function
Distinctly different improvement patterns for BDNF-Met carri-
ers vs. non-carriers became apparent when examining the data 
FigUre 3 | Post-therapy improvement according to BDnF genotype and motor function. Post-therapy improvement on the WMFT-tt (a) and FMA (B) for 
BDNF Met carriers (black) and non-Met carriers (white) with high, moderate, and low motor function. Improvement is illustrated as percentage change from 
pre-therapy score (mean and SE). There was a significant interaction between BDNF genotype and motor function for the WMFT-tt (p = 0.029), whereby the Met 
allele was associated with lower proportional improvement for patients with high (p = 0.046) and moderate (p = 0.008), but not low motor function (a). The same 
pattern was observed for FMA data (B), which was more sensitive to improvements made by patients with low motor function, although this did not reach statistical 
significance (*p < 0.05). For detailed breakdown of the number of carriers/non-carriers with each level of motor function, please refer to Table 2.
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according to patients’ level of residual motor function. Met carriers 
with high and moderate motor function improved by 50 and 25%, 
respectively, compared to non-carriers, while the Val66Met poly-
morphism had no significant effect for patients with low motor 
function (see Figure 3). There was even some suggestion of greater 
average improvement for Met carriers relative to non-carriers in 
the low motor function subgroup, although this reversed pattern 
did not reach statistical significance. The interaction between 
BDNF genotype and motor status suggests the improvement for 
patients with different levels of motor ability may be mediated by 
different mechanisms. We hypothesize that patients with high and 
moderate motor function may rely primarily on cortical plasticity 
processes that are directly affected by the Val66Met polymor-
phism, while those with low motor function and possibly more 
extensive cortical damage, rely more on subcortical plasticity 
processes that are less influenced by BDNF (27). Improvement in 
patients with low residual motor function may also relate to the 
extent of primary damage and the integrity of remaining cortical 
structures available to generate motor output (59), making a more 
subtle effect of genotype difficult to discern in this cohort.
In acute stroke, Di Lazzaro and colleagues recently dem-
onstrated that the BDNF-Val66Met polymorphism can have 
a differential effect on intracortial excitability parameters (60). 
Non-carriers of the polymorphism were seen to have greater 
excitability changes poststroke, with more pronounced hemi-
spheric differences in the balance of excitability. It is possible that 
the functional relevance of such excitability changes may vary 
according to the amount of damage, and hence residual impair-
ment poststroke (61, 62). This may be one mechanism via which 
BDNF genotype may interact with baseline motor function to 
influence motor outcomes, although further investigations that 
incorporate genetic, motor, and cortical excitability testing in the 
chronic period are necessary.
An interaction between BDNF genotype and baseline motor 
function may help explain the lack of consensus in the literature 
regarding the role of the Val66Met polymorphism in stroke 
recovery (27). In the present study, a significant effect of Val66Met 
across the pooled cohort was only apparent after stratifying the 
cohort according to motor function. In previous negative trials 
[e.g., Ref. (16, 33, 34)], significant gene effects may have been 
masked by considering only pooled data from a cohort with varied 
motor function. Thus, stratification according to motor-function 
status may be necessary to elucidate gene effects in heterogeneous 
cohorts in chronic stroke. Our data also provide further evidence 
for the clinical utility of the stratification scheme developed by 
Thompson-Butel and colleagues (51).
implications for Therapy Prescription, 
Dosage, and Trial Design
An important finding from this study is that while the Val66Met 
polymorphism has the capacity to influence the relative magnitude 
of improvement following a standard dose of therapy, neither the 
BDNF-66Met nor the APOE-ε4 allele precludes improvement. Post-
therapy improvements were evident in all patients including carriers 
of both the Met and ε4 alleles and across all levels of baseline motor 
function (Figures  2 and 3). While improvements may be more 
modest for Met carriers compared to non-carriers, it should not be 
assumed that Met carriers do not have the capacity for improvement. 
In the present study, we quantified improvements after a standardized 
dose of therapy and so cannot be certain whether Met carriers would 
have achieved similar gains to non-carriers given additional or more 
intensive therapy. There is some suggestion that intensive training 
in a healthy population can overcome the effect of the Val66Met 
polymorphism with regard to short-term plasticity (63), and thus 
it is possible that a higher dose or more intensive therapy may also 
lessen the impact of the polymorphism in poststroke populations.
Our results suggest that BDNF genotype and baseline 
motor function together have important implications for 
therapy prescription and clinical trial design. We propose that 
this information should inform how therapy programs are 
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structured and what therapy outcomes can be expected and 
not categorize who should or should not receive rehabilitation. 
Our data suggest that future studies should investigate if Met 
carriers with high and moderate motor function require more 
intensive therapy or longer therapy duration than non-carriers 
to achieve a comparable magnitude of improvement. Patients 
with low motor function made significantly less improvement 
on the WMFT-tt compared to those with higher baseline func-
tion, suggesting they may require a larger therapy dose and/
or intensity regardless of BDNF genotype. However, FMA and 
MALQOM data confirm that substantial improvements were 
also evident in patients with low motor function when assessed 
using tools more appropriate for their motor-function status 
(Figures  2 and 3B). The observed effect of BDNF genotype 
and residual motor function on the magnitude of post-therapy 
improvement suggests that stratification may be advisable 
in future clinical trials investigating rehabilitation efficacy 
to ensure balance between trial arms. This would enable the 
inclusion of Met carriers and/or patients with low motor func-
tion without introducing inadvertent study bias and would so 
improve the generalizability of results.
On initial inspection, post-therapy WMFT-tt and FMA data 
may appear incongruous, whereby patients with low motor 
function appear to make greater improvements according to 
the FMA, while patients with high and moderate motor func-
tion appear to improve more on the WMFT-tt (see Figure 3). 
We interpret this as a reflection of the sensitivity of these two 
assessment tools for patients with different levels of motor 
function. It is well established that the WMFT-tt can have a 
prominent floor effect for patients with low motor function, 
while the FMA can have limited sensitivity and a ceiling effect 
for those with high motor function (58, 64–66). Thus, both 
these assessments have differing sensitivity across the spectrum 
of poststroke motor impairment, emphasizing that a suite of 
complementary assessment tools is more informative than 
any single assessment (58). Our MALQOM data support this 
interpretation by demonstrating prominent therapy-induced 
improvements for patients across the entire cohort, from low 
to high motor function (see Figure 2C). Moreover, the same 
pattern of interaction between BDNF genotype and motor 
function was evident for both WMFT-tt and FMA data, regard-
less of apparent differences in improvement magnitude (see 
Figure 3). It is likely that limited FMA sensitivity for patients 
with high and moderate motor function contributed to this 
genotype by motor-function interaction not reaching statistical 
significance for FMA data.
study limitations
While considerable in size for a chronic intervention study, we 
acknowledge this is a small sample for genetic analyses. We, 
therefore, adopted a candidate gene rather than genome-wide 
approach and focused on two polymorphisms that are the best 
characterized and prevalent in the population. Our sample 
included sufficient BDNF-Met carriers to enable the investigation 
of an interaction between BDNF genotype and motor function. 
A lower proportion of ε4 carriers precluded this analysis for APOE 
and likely contributed to our lack of significant APOE findings. 
Statistical power limited our investigation to the comparison of 
“carriers” vs. “non-carriers,” and thus, we cannot comment on 
any possible gene dosage effects for heterozygotes compared to 
homozygotes. Similarly, we were not able to investigate possible 
gene–gene interactions, which may be of interest (67, 68).
Stroke is a heterogeneous disease in many ways, and here, we 
focus on clinical motor heterogeneity. A much larger data set is 
required to consider the influence of additional covariates, such 
as age (69), sex (70, 71), stroke etiology (72, 73), and time post-
stroke, that have the capacity to interact and therefore introduce 
complex variability. We acknowledge that inclusion of two dif-
ferent therapy modalities may have introduced subtle variability, 
where a lack of significant difference between the groups may 
not necessarily indicate statistical equivalence. However, use of 
a combined cohort provided superior statistical power for our 
primary genetic analyses of interest, as in a previous study (16).
cOnclUsiOn
This study identified a novel and significant interaction between 
BDNF-Val66Met genotype and motor function on the magni-
tude of improvement following a protocol of post-acute stroke 
rehabilitation. Here, the BDNF-Met allele was associated with less 
proportional improvement following a standard dose of therapy 
for patients with high and moderate, but not low motor function. 
These data suggest that different mechanisms of recovery may 
be important for patients of different levels of residual voluntary 
motor capacity, and stratification according to motor function 
may be necessary to elucidate gene effects in heterogeneous 
stroke cohorts. Neither the BDNF-66Met nor the APOE-ε4 
allele precluded improvement in carriers, emphasizing that given 
appropriate rehabilitation both carriers and non-carriers retain 
the capacity for improvement. Thus, we propose genetic informa-
tion should be used to guide optimal therapy prescription and 
enable stratification in clinical trials, rather than to determine 
therapy allocation.
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